ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Avon, four companies Fund NABCO Patient Information Services

January 28, 1994

DRCCA Board, Subcommittee Approve Reorganization Of Education Program

February 5, 1982

Prime Contract Subcontract Opportunities

January 24, 1975

In Brief: Ozer, Comis Join Allegheny Cancer Centers; Two Cooperative Groups Under Same Roof

March 21, 1997

New Treatment For Malignant Glioma, IL13-PE38, Tested In Early Clinical Trials

December 28, 2001

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

February 25, 2011